Compare ResMed Inc. (RMD) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs UBS Group AG Registered Ordinary Shares — how do they compare? ResMed Inc. trades at $230.5 (market cap $31.89B), while UBS Group AG Registered Ordinary Shares trades at $48.19 (market cap $142.70B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 4.5× ResMed Inc.'s market cap, and UBS Group AG Registered Ordinary Shares pays the higher dividend (2.34%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and UBS Group AG Registered Ordinary Shares for 1 Days on average.
| RMD | UBS | |
|---|---|---|
Market Cap | $31.89B | $142.70B |
Volume | 618,314 | 2,096,090 |
Sector | Health | Financials |
52-Week High | $277.88 | $55.72 |
52-Week Low | $182.82 | $36.41 |
Typical Hold Time | 51 Days | 1 Days |
Enterprise Value | $31.24B | $314.41B |
Dividend Yield | 1.16% | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
